BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38698538)

  • 21. Precision oncology in the age of integrative genomics.
    Kumar-Sinha C; Chinnaiyan AM
    Nat Biotechnol; 2018 Jan; 36(1):46-60. PubMed ID: 29319699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Precision oncology and molecular tumor boards].
    Mack E; Horak P; Fröhling S; Neubauer A
    Inn Med (Heidelb); 2024 May; 65(5):462-471. PubMed ID: 38652307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

  • 24. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalised medicine in veterinary oncology: one to cure just one.
    Klopfleisch R
    Vet J; 2015 Aug; 205(2):128-35. PubMed ID: 25641551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future Clinical Trials: Genetically Driven Trials.
    Astsaturov I
    Surg Oncol Clin N Am; 2017 Oct; 26(4):791-797. PubMed ID: 28923231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical interpretation of whole-genome and whole-transcriptome sequencing for precision oncology.
    Jobanputra V; Wrzeszczynski KO; Buttner R; Caldas C; Cuppen E; Grimmond S; Haferlach T; Mullighan C; Schuh A; Elemento O
    Semin Cancer Biol; 2022 Sep; 84():23-31. PubMed ID: 34256129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular testing in oncology: problems, pitfalls and progress.
    O'Brien CP; Taylor SE; O'Leary JJ; Finn SP
    Lung Cancer; 2014 Mar; 83(3):309-15. PubMed ID: 24472389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implementing precision cancer medicine in the genomic era.
    Chen HZ; Bonneville R; Roychowdhury S
    Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
    Beer PA; Cooke SL; Chang DK; Biankin AV
    Ann Oncol; 2019 Nov; 30(11):1691-1694. PubMed ID: 31665210
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [From panel diagnostics to comprehensive genomic analysis : Infobesity or empowerment?].
    Leichsenring J; Kazdal D; Ploeger C; Allgäuer M; Endris V; Volckmar AL; Neumann O; Kirchner M; Penzel R; Rempel E; Budczies J; Schirmacher P; Fröhling S; Stenzinger A
    Pathologe; 2019 May; 40(3):235-242. PubMed ID: 31089797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
    Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
    Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
    [No Abstract]   [Full Text] [Related]  

  • 36. Understanding inequities in precision oncology diagnostics.
    Dutta R; Vallurupalli M; McVeigh Q; Huang FW; Rebbeck TR
    Nat Cancer; 2023 Jun; 4(6):787-794. PubMed ID: 37248397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Network science in clinical trials: A patient-centered approach.
    Manem VSK; Salgado R; Aftimos P; Sotiriou C; Haibe-Kains B
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):135-150. PubMed ID: 29278737
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment.
    Schmidt KT; Chau CH; Price DK; Figg WD
    J Clin Pharmacol; 2016 Dec; 56(12):1484-1499. PubMed ID: 27197880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Personalized medicine in oncology].
    Lörsch AM; Jung J; Lange S; Pfarr N; Mogler C; Illert AL
    Pathologie (Heidelb); 2024 May; 45(3):180-189. PubMed ID: 38568256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
    Kotelnikova EA; Pyatnitskiy M; Paleeva A; Kremenetskaya O; Vinogradov D
    Oncotarget; 2016 Aug; 7(32):52493-52516. PubMed ID: 27191992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.